Stephanie Richards is a partner in Goodwin’s nationally recognized Life Sciences group, counseling private and public companies at all life cycle stages.
Stephanie has extensive experience with startup and formation matters, venture capital and growth financings, initial public offerings, capital markets transactions, mergers and acquisitions, and other complex transactions. She also represents a number of publicly traded biotechnology companies and their boards of directors in ongoing SEC compliance, capital raising and corporate governance matters as well as leading venture capital firms focused on the life sciences industry in connection with their portfolio company investments and exits. Advising companies throughout the full range of the corporate life cycle, Stephanie has worked with many of her clients since their initial founding and funding through their initial public offering and strategic exit. She joined Goodwin in 2018.
Experience
- Rapport Therapeutics in its $174.4 million initial public offering and concurrent private placement, $150 million “at-the-market” offering and $250 million follow on offering
- Ikena Oncology in its $75 million PIPE in connection with its merger with Inmagene Biopharmaceuticals
- Aura Biosciences in its $75.6 million initial public offering, $75 million “at-the-market” offering, $80.4 million follow on offering, $99 million follow on offering and $75 million follow on offering
- Kazia Therapeutics in its at-the-market offerings, various private placements and equity lines of credit
- Disc Medicine in its $137 million follow on offering
- Ikena Oncology in its $133.6 million initial public offering, and in its $100 million “at-the-market” offering and $40 million underwritten offering
- SpringWorks Therapeutics in its $225 million PIPE financing
- Kymera Therapeutics in its $150 million PIPE financing
- Flagship Pioneering in its investment in a PIPE financing by Syros Pharmaceuticals
- Olink Holding AB (publ) in its $264 million initial public offering, $232.5 million secondary public offering, and $80.75 million follow on offering
- iTeos Therapeutics in its $201 million initial public offering
- The underwriters in Tufin Software Technologies’ $107.8 million initial public offering
- The underwriters in Freeline Therapeutics Holdings plc’s $159 million initial public offering
- Xeris Pharmaceuticals in its $85.5 million initial public offering, subsequent debt and equity follow on offerings
- TCR2 Therapeutics in its $75 million initial public offering and subsequent equity follow on offerings
- Forbion in its investment in MapLight Therapeutics’ $372.5 million Series D financing
- Avalyn Pharma in its $100 million Series D financing
- Rapport Therapeutics in its $100 million Series A financing and $150 million Series B financing
- Repertoire Immune Medicines in its $189 million Series B financing
- Third Rock Ventures in its investment in Synnovation Therapeutics’ $102 million Series A financing
- Aura Biosciences in its $80 million Series E financing
- Ikena Oncology in its $120 million Series B financing
- Faze Medicines in its $81 million Series A financing
- Thrive Earlier Detection Corp. in its $110 million Series A financing and $257 million Series B financing
- iTeos Therapeutics in its $125 million Series B financing
- Flagship Pioneering in connection with their company formation and financing related matters
- Third Rock Ventures in connection with their company formation and financing related matters
- Ikena Oncology in its merger with Inmagene Biopharmaceuticals
- Fusion Pharmaceuticals in its sale to AstraZeneca
- Alkermes in the spin off of its oncology business into Mural Oncology as a separate public company
- Ikena Oncology in its acquisition of Pionyr Immunotherapeutics
- TCR2 Therapeutics in its cross-border sale to Adaptimmune
- Akston Biosciences in its sale of certain assets to Dechra Limited
- Disc Medicine in connection with its reverse merger transaction with Gemini Therapeutics
- Xeris Pharmaceuticals in its cross-border acquisition of Strongbridge Biopharma
- Inzen Therapeutics in its merger with Cygnal Therapeutics
- Valo Health in its announced 2021 deSPAC business combination with Khosla Ventures Acquisition Co.
- Cogen Immune Medicines in its merger with Torque Therapeutics
Professional Activities
Stephanie serves on the Board of Directors of Hospitality Homes, a Boston-based nonprofit organization pairing patients and their caregivers with living accommodations during medical treatments, helping to increase access to lifesaving treatments.
Credentials
Education
JD2013
Duke University School of Law
LLM2013
Duke University School of Law
BAEnglish2010
Yale College
Admissions
Bars
- Massachusetts
- California
Recognition & Awards
Stephanie has been recognized by The Best Lawyers in America for her work in Corporate Law in 2025 and 2026.